{"title":"嗜中性粒细胞与淋巴细胞比值升高可作为检测 1 型嗜睡症患者神经炎症的标记。","authors":"Matteo Conti, Flavia Cirillo, Silvia Maio, Mariana Fernandes, Roberta Bovenzi, Fabio Placidi, Francesca Izzi, Nicola Biagio Mercuri, Claudio Liguori","doi":"10.5664/jcsm.11368","DOIUrl":null,"url":null,"abstract":"<p><strong>Study objectives: </strong>Narcolepsy type 1 (NT1) is an autoimmune disease caused by the selective attack of orexin-producing neurons. However, the pathophysiology of narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) remains controversial. The neutrophil-to-lymphocyte ratio (NLR) is an easily calculated parameter from the white blood cell (WBC) count, which has already been extensively used as an inflammatory marker in immunological disorders. In this study, by examining the WBC counts of patients with NT1, NT2, and IH compared to controls, and evaluated the NLR to test the possibility of identifying an easy biofluid marker for detecting inflammation and distinguishing patients from healthy controls (HC).</p><p><strong>Methods: </strong>WBC counts and NLR were compared in 28 NT1, 17 NT2, and 11 IH patients, in addition to 21 sex/age-matched HC. These parameters were correlated with cerebrospinal fluid (CSF) levels of orexin-A, the CSF/serum albumin ratio (as a marker of blood-brain barrier integrity), and polysomnographic parameters.</p><p><strong>Results: </strong>NT1 (2.01±0.44) patients showed higher NLR than NT2 (1.59±0.53), IH (1.48±0.37), and HC (1.48±0.43), with no significant difference between NT2 and IH patients. The ROC curve analysis detected an optimal cut-off value to discriminate patients with NT1 from NT2, IH, and HC for values of NLR≥1.60, 1.62, 1.59, respectively.</p><p><strong>Conclusions: </strong>Patients with NT1 showed a higher NLR than those with NT2, IH, and HC, possibly reflecting lymphocyte migration within the CNS, supporting the hypothesis of a neuroinflammatory attack of lymphocytes on orexin-producing neurons. Considering its sensitivity, this easily obtainable biofluid marker could help to screen NT1 patients.</p>","PeriodicalId":50233,"journal":{"name":"Journal of Clinical Sleep Medicine","volume":" ","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Increased neutrophil to lymphocyte ratio as a possible marker to detect neuroinflammation in patients with narcolepsy type 1.\",\"authors\":\"Matteo Conti, Flavia Cirillo, Silvia Maio, Mariana Fernandes, Roberta Bovenzi, Fabio Placidi, Francesca Izzi, Nicola Biagio Mercuri, Claudio Liguori\",\"doi\":\"10.5664/jcsm.11368\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Study objectives: </strong>Narcolepsy type 1 (NT1) is an autoimmune disease caused by the selective attack of orexin-producing neurons. However, the pathophysiology of narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) remains controversial. The neutrophil-to-lymphocyte ratio (NLR) is an easily calculated parameter from the white blood cell (WBC) count, which has already been extensively used as an inflammatory marker in immunological disorders. In this study, by examining the WBC counts of patients with NT1, NT2, and IH compared to controls, and evaluated the NLR to test the possibility of identifying an easy biofluid marker for detecting inflammation and distinguishing patients from healthy controls (HC).</p><p><strong>Methods: </strong>WBC counts and NLR were compared in 28 NT1, 17 NT2, and 11 IH patients, in addition to 21 sex/age-matched HC. These parameters were correlated with cerebrospinal fluid (CSF) levels of orexin-A, the CSF/serum albumin ratio (as a marker of blood-brain barrier integrity), and polysomnographic parameters.</p><p><strong>Results: </strong>NT1 (2.01±0.44) patients showed higher NLR than NT2 (1.59±0.53), IH (1.48±0.37), and HC (1.48±0.43), with no significant difference between NT2 and IH patients. The ROC curve analysis detected an optimal cut-off value to discriminate patients with NT1 from NT2, IH, and HC for values of NLR≥1.60, 1.62, 1.59, respectively.</p><p><strong>Conclusions: </strong>Patients with NT1 showed a higher NLR than those with NT2, IH, and HC, possibly reflecting lymphocyte migration within the CNS, supporting the hypothesis of a neuroinflammatory attack of lymphocytes on orexin-producing neurons. Considering its sensitivity, this easily obtainable biofluid marker could help to screen NT1 patients.</p>\",\"PeriodicalId\":50233,\"journal\":{\"name\":\"Journal of Clinical Sleep Medicine\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.5000,\"publicationDate\":\"2024-09-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Clinical Sleep Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.5664/jcsm.11368\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Sleep Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5664/jcsm.11368","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
研究目的1 型嗜睡症(NT1)是一种选择性攻击产生奥曲肽的神经元而导致的自身免疫性疾病。然而,2型嗜睡症(NT2)和特发性嗜睡症(IH)的病理生理学仍存在争议。中性粒细胞与淋巴细胞比值(NLR)是从白细胞(WBC)计数中计算出来的一个简单参数,已被广泛用作免疫性疾病的炎症标志物。在本研究中,通过检测 NT1、NT2 和 IH 患者与对照组相比的白细胞计数,并评估 NLR,以检验是否有可能找到一种简便的生物流体标记物来检测炎症并将患者与健康对照组(HC)区分开来:方法:比较了28名NT1、17名NT2和11名IH患者以及21名性别/年龄匹配的HC患者的白细胞计数和NLR。这些参数与脑脊液(CSF)中的奥曲肽-A水平、CSF/血清白蛋白比值(血脑屏障完整性的标志)以及多导睡眠图参数相关:NT1患者(2.01±0.44)的NLR高于NT2(1.59±0.53)、IH(1.48±0.37)和HC(1.48±0.43),NT2和IH患者之间无显著差异。ROC曲线分析发现,NLR≥1.60、1.62和1.59的数值是区分NT1和NT2、IH和HC患者的最佳临界值:结论:NT1患者的NLR高于NT2、IH和HC患者,可能反映了淋巴细胞在中枢神经系统内的迁移,支持淋巴细胞对产生奥曲肽的神经元进行神经炎症攻击的假设。考虑到其灵敏性,这种容易获得的生物流体标记物有助于筛查NT1患者。
Increased neutrophil to lymphocyte ratio as a possible marker to detect neuroinflammation in patients with narcolepsy type 1.
Study objectives: Narcolepsy type 1 (NT1) is an autoimmune disease caused by the selective attack of orexin-producing neurons. However, the pathophysiology of narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) remains controversial. The neutrophil-to-lymphocyte ratio (NLR) is an easily calculated parameter from the white blood cell (WBC) count, which has already been extensively used as an inflammatory marker in immunological disorders. In this study, by examining the WBC counts of patients with NT1, NT2, and IH compared to controls, and evaluated the NLR to test the possibility of identifying an easy biofluid marker for detecting inflammation and distinguishing patients from healthy controls (HC).
Methods: WBC counts and NLR were compared in 28 NT1, 17 NT2, and 11 IH patients, in addition to 21 sex/age-matched HC. These parameters were correlated with cerebrospinal fluid (CSF) levels of orexin-A, the CSF/serum albumin ratio (as a marker of blood-brain barrier integrity), and polysomnographic parameters.
Results: NT1 (2.01±0.44) patients showed higher NLR than NT2 (1.59±0.53), IH (1.48±0.37), and HC (1.48±0.43), with no significant difference between NT2 and IH patients. The ROC curve analysis detected an optimal cut-off value to discriminate patients with NT1 from NT2, IH, and HC for values of NLR≥1.60, 1.62, 1.59, respectively.
Conclusions: Patients with NT1 showed a higher NLR than those with NT2, IH, and HC, possibly reflecting lymphocyte migration within the CNS, supporting the hypothesis of a neuroinflammatory attack of lymphocytes on orexin-producing neurons. Considering its sensitivity, this easily obtainable biofluid marker could help to screen NT1 patients.
期刊介绍:
Journal of Clinical Sleep Medicine focuses on clinical sleep medicine. Its emphasis is publication of papers with direct applicability and/or relevance to the clinical practice of sleep medicine. This includes clinical trials, clinical reviews, clinical commentary and debate, medical economic/practice perspectives, case series and novel/interesting case reports. In addition, the journal will publish proceedings from conferences, workshops and symposia sponsored by the American Academy of Sleep Medicine or other organizations related to improving the practice of sleep medicine.